TiGenix S.A.

Cellerix SA is a Spanish private biopharmaceutical company dedicated to the development, production and commercialization of innovative stem cell based medicinal products. The Company is leading the development of a new generation of off-the-shelf products using expanded adult stem cells from adipose tissue (eASCs). Cellerix has shown that eASCs have strong anti-inflammatory and immunomudalatory properties and, as such, could represent a revolution in the treatment of autoimmune and inflammatory diseases which to date represent an area of high medical unmet need. Development is at a clinically advanced stage with promising results having been obtained in phase I and II clinical trials. Cellerix’ platform is based on an extensive preclinical and regulatory package that has been fully validated according to EMA requirements. The products are manufactured in Cellerix’ GMP facility in Madrid. The current pipeline includes Cx601 (orphan drug,) which received positive Phase IIa data for the treatment of complex perianal fistula in Crohn’s disease patients in 2010, Cx611, which has received authorization to start a Phase I/II trial in rheumatoid arthritis and several other programs in earlier development. *

	Start	2012-08-23 renamed before
	End	2012-08-23 renamed before
	Group	Takeda (Group)
	Predecessor	Cellerix S.A.
	Industry	stem cell therapy
	Person	Bravo, Eduardo (Life Sciences Partners 202103– Partner + CEO of EBAC before Nordic Nanovector + TiGenix + Cellerix)

	Region	Madrid
	Country	Spain (España)

Basic data	Employees	n. a.

		* Document for »About Section«:

		Record changed: 2023-07-10